tradingkey.logo
tradingkey.logo
Search

PharmaCyte Biotech Inc

PMCB
Add to Watchlist
0.584USD
-0.016-2.67%
Close 07-31 16:00ETQuotes delayed by 15 min
6.27MMarket Cap
LossP/E TTM

PharmaCyte Biotech Inc

0.584
-0.016-2.67%
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-2.67%

5 Days

-2.68%

1 Month

-24.16%

6 Months

-28.69%

Year to Date

-19.34%

1 Year

-42.75%

Key Figures
0.597Open
0.600High
155.91KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
1.45%Turnover Ratio
0.600Prev. Close
0.562Low
57.28KTurnover
0.27P/E Static
0.19P/B
0.00%Div Yield TTM
-6.58%ROA
1.51052wk High
0.77Volume Ratio
23.36MNet Profit
10.74MShares
-0.8906EPS TTM
0.50Beta
-19.01%ROE
0.63052wk Low
6.37%Amplitude
--Gross Margin
6.27MMarket Cap
-2.89Reward/Risk
5.57%Risk Rate

Key Insights

PharmaCyte Biotech Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 192 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

PharmaCyte Biotech Inc's Score

Industry at a Glance

Industry Ranking
192 / 385
Overall Ranking
355 / 4281
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

PharmaCyte Biotech Inc Highlights

StrengthsRisks
PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -0.65, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.07M shares, increasing 24.50% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space

PharmaCyte Biotech Inc News

More news coming soon, stay tuned...

Indicators

Indicators
Sell(3)
Neutral(2)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.007
Sell
RSI(14)
32.774
Neutral
STOCH(KDJ)(9,3,3)
31.708
Buy
ATR(14)
0.046
High Vlolatility
CCI(14)
-89.204
Neutral
Williams %R
86.309
Oversold
TRIX(12,20)
-0.951
Sell
StochRSI(14)
26.821
Sell
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
0.587
Sell
MA10
0.598
Sell
MA20
0.644
Sell
MA50
0.715
Sell
MA100
0.723
Sell
MA200
0.781
Sell

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

PharmaCyte Biotech Inc Info

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
Ticker SymbolPMCB
CompanyPharmaCyte Biotech Inc
CEOSilverman (Joshua N)
Websitehttps://pharmacyte.com/

Shareholders

Shareholders
Shareholders
Proportion
Silverman (Joshua)
3.41%
Citadel Advisors LLC
2.14%
HRT Financial LP
1.70%
Schechter (Jonathan L)
1.23%
Geode Capital Management, L.L.C.
1.15%
Other
90.36%

FAQs

What is the current price of PharmaCyte Biotech Inc (PMCB)?

The current price of PharmaCyte Biotech Inc (PMCB) is 0.58.

What is the symbol of PharmaCyte Biotech Inc?

The ticker symbol of PharmaCyte Biotech Inc is PMCB.

What is the 52-week high of PharmaCyte Biotech Inc?

The 52-week high of PharmaCyte Biotech Inc is 1.51.

What is the 52-week low of PharmaCyte Biotech Inc?

The 52-week low of PharmaCyte Biotech Inc is 0.63.

What is the market capitalization of PharmaCyte Biotech Inc?

The market capitalization of PharmaCyte Biotech Inc is 6.27M.

What is the Earnings Per Share (EPS TTM) of PharmaCyte Biotech Inc (PMCB)?

The Earnings Per Share (EPS TTM) of PharmaCyte Biotech Inc (PMCB) is -2.77.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.